Go to Top

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer.

Board of Directors

Board of Directors

Douglas Reed, M.D.
General Partner, Hatteras Venture Partners, Chairman

Dr. Reed joined Hatteras Venture Partners as a General Partner in early 2007. Prior to Hatteras, Doug had 14 years of venture investing experience with two healthcare-focused funds, Vector Fund Management and SR One. He has been involved in venture investment transactions for over 30 healthcare and life science companies and currently serves as chairman of Viamet Pharmaceuticals Holdings, LLC, and as director of TetraLogic Pharmaceuticals and several private life sciences companies.

Andrew von Eschenbach, M.D.

Dr. von Eschenbach was the Commissioner of the US Food and Drug Administration from 2005 to 2009. Previously, Dr. von Eschenbach was Director of the US National Cancer Institute. Prior to his government service, he was an accomplished urologist and healthcare administrator. His medical career included several leadership roles at the University of Texas M.D. Anderson Cancer Center including Chair of the Department of Urology, founding Director of the Prostate Cancer Research Program, Director of the Genitourinary Cancer Center, Distinguished Chair in Urologic Oncology, and Executive Vice President and Chief Academic Officer.

Fred Eshelman, PharmD.
CEO and Director

Fred Eshelman is the founder and principle of Eshelman Ventures LLC, investing in a variety of companies, primarily health care.  Prior to that, he was the founding chairman of Furiex Pharmaceuticals (FURX, NASDAQ); the company was sold to Forest Labs/Actavis in July, 2014.

Previously, he found and served as CEO and Executive Chairman of Pharmaceutical Product Development, Inc. (PPDI, NASDAQ) until sale of the company to private equity interests (Carlyle, Hellman & Friedman).  His career has also included positions as Senior Vice President, Development and board member of Glaxo Inc., as well as various management positions at Beecham Laboratories and Boehringer Mannheim Pharmaceuticals.  He serves on a number of industry boards.

He is active in higher education, serving on the Board of Governors for the UNC System (chaired Audit Committee) and as an adjunct professor at the UNC School of Pharmacy, where he chairs the Board of Visitors.  One of the top pharmacy programs in the US, in May 2008 the school was named the Eshelman School of Pharmacy, in recognition of his many contributions to the school and profession.

Dr. Eshelman holds a BSc pharmacy from UNC-CH, a doctor of pharmacy from the University of Cincinnati and completed a hospital residency at Cincinnati General Hospital.  He completed the Owner/President/Manager program at Harvard Business School.

Richard Kent, M.D.
General Partner, Intersouth Partners

Richard Kent, M.D. is a Venture Partner with Intersouth Partners, one of the largest and most experienced venture capital funds in the southeast.  Dr. Kent has more than 30 years of global pharmaceutical experience.  Most recently he was CEO of Serenex, Inc., a venture backed biotechnology company acquired by Pfizer. Prior executive positions include CEO of Ardent Pharmaceuticals and Senior Vice President, Global Medical Affairs as well as Chief Medical Officer of GlaxoSmithKline.  Dr. Kent has supervised dozens of INDs and over 20 successful NDAs (and equivalent submissions in Europe and the rest of the world) across a wide range of therapeutic areas including Oncology.

Dr. Kent received his undergraduate degree from the University of California, Berkeley and his medical degree from the University of California, San Diego. He completed his medical training at Harvard (Peter Bent Brigham Hospital), Stanford University Medical Center and Duke University Medical Center, and was a member of Duke University’s medical faculty.  He is board certified in both internal medicine and cardiology.

Robert Schotzinger, M.D., Ph.D.
President & CEO, Viamet Pharmaceuticals

Dr. Schotzinger brings over 20 years of research, development and management experience to Viamet Pharmaceuticals, where he has raised significant equity capital and moved Viamet Pharmaceuticals from a seed-stage company to a clinical-stage company. Prior to joining Viamet Pharmaceuticals, Dr. Schotzinger was President and CEO of BioStratum Inc., a privately-held biotechnology company, where he was responsible for moving the company’s lead drug candidate from phase 1 to phase 3. Dr. Schotzinger began his pharmaceutical career at Abbott Laboratories where he held positions of increasing responsibility, including Director of International Medical Affairs and Vice President of Drug Development. While at Abbott, he gained experience in preclinical and clinical drug development and was involved in the filing and approval of multiple NDAs, SNDAs, ANDAs and INDs.

Dr. Schotzinger received his B.S. in Pharmacy from the Ohio State University. He subsequently earned his Ph.D. degree in pharmacology and medical degree from Case Western Reserve University. He also completed a residency at the University of Virginia, which led to Board Certification in Internal Medicine.

S. Edward Torres
Managing Director, Lilly Ventures

Mr. Torres is a managing director of Lilly Ventures Fund I LLC and brings over 20 years of pharmaceutical and venture capital experience to the team. Ed currently sits on the boards of Viamet Pharmaceuticals Holdings, LLC, Receptos, several private life sciences companies and various non-profit institutions. Prior to his role in Lilly Ventures, Ed had a diverse set of experiences throughout the domestic and international pharmaceutical businesses of Eli Lilly including operational finance, planning, M&A, business development and global marketing roles. Ed received a B.A. from Creighton University and a M.B.A. from the University of Michigan Business School, where he was a Consortium Fellow.

Steven Weinstein
Managing Director, Novartis Venture Fund

Steve focuses on both bio/pharma and medical device investments for the fund. He brings significant operating and venture capital experience to Novartis’ investing efforts. Steve joined the Fund in 2006 as a Managing Director. He serves/d on the board of the following companies: Ablation Frontiers (acquired by Medtronic), Advanced Animal Diagnostics, Autonomic Technologies Inc., Intersection Medical, Sonitus Medical, Viamet Pharmaceuticals, and Visiogen (acquired by Abbott). Prior to Novartis, Steve was at Prism Venture Partners, where he focused on medical devices and served on the boards of iScience Interventional, and Sensitech (acquired by Carrier/UTX). Prior to Prism, Steve was a Kauffman Fellow with Mid-Atlantic Venture Funds. He started his career as an entrepreneur and CEO, raising angel funds to buy the assets of a defunct distribution business out of bankruptcy, and then rebuilt the business over the next five years. Steve holds an MBA with distinction from the University of Michigan Business School and a BS in mechanical engineering from Columbia University’s School of Engineering and Applied Science. He serves on the Innovation Advisory Board of Partners Healthcare, and is a member of the Virginia GAP BioLife Fund Investment Committee, on the advisory board of the Wolverine Venture Fund (affiliated with the University of Michigan), and previously served on the Innovation Advisory Board of the Cleveland Clinic.

Kristopher Wood
Chief Investment Officer, Lurie Holdings Inc.

Kristopher is the chief investment officer at Lurie Holdings Inc. Prior to Lurie Holdings, he served as head of strategy and corporate development at World Color, a printing company. Previously, he was also an associate at MidOcean Partners, a private equity company. Kris also served as chief acquisitions officer for Glenayre Inc. and as managing director for mergers and acquisitions and venture capital at Vertis Holdings, Inc. Kris serves on the board of directors of several private companies. He received a B.S. from the Wharton School of the University of Pennsylvania.